Loading...

Innovent Biologics, Inc.

1801.HK•HKSE
Healthcare
Biotechnology
HK$77.35
HK$-5.05(-6.13%)

Innovent Biologics, Inc. (1801.HK) Stock Overview

Explore Innovent Biologics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.7/100

Key Financials

Market Cap129.8B
P/E Ratio-1243.95
EPS (TTM)$-0.06
ROE-0.01%

AI Price Forecasts

1 Week$75.39
1 Month$76.27
3 Months$45.43
1 Year Target$33.61

1801.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Innovent Biologics, Inc. (1801.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 84.17, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $33.61.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1243.95 and a market capitalization of 129.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

84.17RSI (14)
6.92MACD
42.95ADX
Stats data is not available for 1801.HKStats details for 1801.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1801.HKAnalyst Recommendations details for 1801.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

CEO

De-Chao Yu

Employees

5,659

Headquarters

168 Dongping Street, Suzhou

Founded

2018

Frequently Asked Questions

;